SAM
ACHN

Senzar Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Senzar Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,082,100
Closed -$4.97M – 37
2017
Q2 		$4.97M Buy
+1,082,100
New +$4.35M 1.22% 19
2015
Q4 		– Sell
-619,000
Closed -$4.28M – 48
2015
Q3 		$4.28M Sell
619,000
-257,000
-29% -$2.09M 0.62% 26
2015
Q2 		$7.76M Buy
876,000
+566,100
+183% +$5.35M 1.33% 27
2015
Q1 		$3.06M Buy
+309,900
New +$3.87M 0.74% 29

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Senzar Asset Management's ACHN Position: Q3 2017 in Review

Senzar Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 1,082,100 shares — an estimated $4.97M sold.

Senzar Asset Management first reported a position in ACHN in Q1 2015 and held it in 4 quarters. The position peaked at $7.76M in Q2 2015. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

  • Senzar Asset Management reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Senzar Asset Management sold 1,082,100 Achillion Pharmaceuticals shares in Q3 2017, an estimated $4.97M.
  • Senzar Asset Management first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Senzar Asset Management's Achillion Pharmaceuticals position peaked at $7.76M in Q2 2015.
  • 125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on Senzar Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.